TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12872395
Drug: Conventional treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment, treated for 3 months
Study: 6330643
Drug: Naloxone (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.8 mg in 2 ml vehicle each)
Study: 31671137
Drug: Caffeine 300
Normalized name: caffeine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 300 mg
Study: 29194531
Drug: Conservative surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative surgery and Radical rectal surgery
Study: 24136379
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg intravenously 2 to 3 hours prior to surgery (Group A)
Study: 15680454
Drug: New cell-cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: New cell-cultured smallpox vaccine (CCSV)
Study: 10665784
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen treatment in 10 fractions (total dose of 45 Gy)
Study: 10665784
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen treatment in 28 fractions
Study: 1796125
Drug: N-desmethyladinazolam (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-desmethyladinazolam (all doses)
Study: 6366027
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy with a mixture of three grass pollen-aqueous extracts (velvet, sweet vernal, and timothy)
Study: 31677701
Drug: Prolonged elemental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged elemental diet (ED) therapy
Study: 24533512
Drug: Social skills
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social skills treatment based on Cognitive Behaviour Therapy principles
Study: 17608739
Drug: Buccally positioned
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccally positioned implants
Study: 17608739
Drug: Lingually positioned
Normalized name: Nitroglycerin Lingual Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lingually positioned implants
Study: 15215086
Drug: 12 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg/kg every 12 h for 3 doses and then 15 mg/kg every 48 h for 4 doses (daily dosing)
Study: 15215086
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg every 12 h for 2 doses and then 6 mg/kg every 24 h for 9 doses (alternate-day dosing)
Study: 9237963
Drug: Olestra 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olestra 20 g
Study: 30019170
Drug: Immediate functional
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate functional loading of short implants (6 mm)
Study: 30019170
Drug: Delayed loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed loading of short implants (6 mm)
Study: 30019170
Drug: Immediate and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate and delayed loading of short implants (6 mm)
Study: 28842139
Drug: Low-dose daunorubicin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose daunorubicin (45 to 60 mg/m2)
Study: 22586902
Drug: intramuscular cycloferon
Normalized name: Cicloferon
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intramuscular cycloferon
Study: 15871639
Drug: Intravenous imipenem
Normalized name: Imipenem
DrugBank: Imipenem (DB01598)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous imipenem 1g plus cilastatin 1g
Study: 15871639
Drug: Intravenous meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous meropenem 1g
Study: 16520833
Drug: Labetalol (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (1.2 mg/kg)
Study: 2908516
Drug: Diazepam (challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (challenge dose)
Study: 21773032
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (ritodrine and magnesium)
Study: 17070175
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg/d for 12 weeks
Study: 17070175
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Policosanol + Atorvastatin)
Study: 6743447
Drug: diamorphine hydrochloride
Normalized name: Diamorphine hydrochloride
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: diamorphine hydrochloride 2 mg
Study: 2872740
Drug: Carotid endarterectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotid endarterectomy and aspirin therapy
Study: 26920606
Drug: Aspirin therapy
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin therapy alone
Study: 25691293
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (palliative therapy)
Study: 22512632
Drug: Inhaled inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled inactivated Mycobacterium phlei
Study: 23413910
Drug: Inhaled Seretide
Normalized name: seractide
DrugBank: Seractide acetate (DB09334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled Seretide
Study: 19380258
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 2 mL lignocaine
Study: 19380258
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 5% hypertonic saline
Study: 16512941
Drug: Incremental yoghurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incremental yoghurt consumption (125 g/d)
Study: 8384733
Drug: Oral vaccine
Normalized name: RotaTeq Oral Vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vaccine
Study: 8488716
Drug: Parenteral vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral vaccine
Study: 2441202
Drug: Captopril (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (mean daily dose 84 mg)
Study: 28971636
Drug: Paracetamol (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1000 mg)
Study: 26286324
Drug: Mitii™ training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitii™ training (20 weeks, 30 min per day, six days a week, total dose of 60 hours)
Study: 21784377
Drug: Rosuvastatin 5
Normalized name: rosuvastatin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 5 mg once-weekly (with titration to 10 mg if not at LDL goal at week 4)
Study: 19270639
Drug: Physiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy plus mesoglycan 50 mg p.o., twice a day
Study: 16521017
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution containing a low dose of norepinephrine
Study: 15753743
Drug: 12 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mL/kg predicted body weight tidal volume
Study: 9401573
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment, 1.0 IU/kg/day, subcutaneous injections from postnatal day 7 until body weight of 2000 g (postnatal week 7-8)
Study: 20546516
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection PVB followed by CPVB infusion of 0.1% or 0.2% ropivacaine
Study: 17915572
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose creatine (60 mg/kg/day)
Study: 17915572
Drug: Oral sucrose
Normalized name: TootSweet 24% Oral Sucrose Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sucrose (75 g prior to exercise)
Study: 11875168
Drug: BUD400 (budesonide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUD400 (budesonide, 200 microg twice daily via pMDI and NebuChamber)
Study: 11875168
Drug: FP400 (fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP400 (fluticasone propionate, 200 microg twice daily via pMDI and Babyhaler)
Study: 10203139
Drug: 17beta-estradiol (E2)
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17beta-estradiol (E2) supplementation at 2.30 mg x kg(‐1) x d(‐1) (1.13‐3.42 mg x kg(‐1) x d(‐1)) and progesterone (P) supplementation at 21.20 mg x kg(‐1) x d(‐1) (11.23‐27.36 mg x kg(‐1) x d(‐1))
Study: 20132529
Drug: Sertraline (50‐100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50‐100 mg/day)
Study: 29247457
Drug: hMG +
Approvals — FDA: no, EMA: no, PMDA: no
Description: hMG + MPA + CC
Study: 22626879
Drug: Nucleos(t)ide therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleos(t)ide therapy (ETV and ADV)
Study: 19608838
Drug: Dexamethasone 15
Normalized name: MENTHOL 200 mg in 20000 mg / CAMPHOR (SYNTHETIC) 200 mg in 20000 mg / DEXAMETHASONE 15 mg in 20000 mg TOPICAL OINTMENT [999 ITCH RELIEF]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 15 mg
Study: 11220429
Drug: Dexamethasone 10
Normalized name: dexamethasone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 10 mg
Study: 11234783
Drug: Patient-delivered partner
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-delivered partner medication (PDPM)
Study: 15235555
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia with propofol and remifentanil
Study: 11465522
Drug: Buspirone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (10 to 30 mg b.i.d.)
Study: 15989452
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream and IV fentanyl 0.25 microg/kg with an occlusive dressing
Study: 15989452
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream and IV fentanyl 0.25 microg/kg with an occlusive dressing
Study: 14500150
Drug: Group 3
Normalized name: Chlamydophila psittaci biogroup 3 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3 (25 mL 0.25% bupivacaine and piroxicam 20 mg)
Study: 10909489
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment with supplementary chemotherapy (EEP cycle: Etoposide, Epirubicin, Cisplatin or 5-fluorouracil)
Study: 10909489
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment with supplementary chemotherapy
Study: 8778851
Drug: Melatonin (MT),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (MT), 5 mg, 2300 h, D6‐D8
Study: 6716468
Drug: Brief daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief daily telephone calls
Study: 31206313
Drug: Simvastatin 80
Normalized name: simvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 80 mg for 7 days
Study: 26116695
Drug: Exenatide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (5 μg)
Study: 31124581
Drug: Dexamethasone (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (6 mg/m2/day)
Study: 31124581
Drug: Prednisolone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (60 mg/m2/day)
Study: 20192935
Drug: Voltaren suppository
Normalized name: Voltarene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voltaren suppository placed in rectum an hour before biopsy
Study: 16286517
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg three times daily for 24 weeks
Study: 8608096
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin (60 mg)
Study: 2212376
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of benazepril and metoprolol OROS
Study: 19291356
Drug: Daily multivitamin
Normalized name: DAILY MULTIVITAMIN TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily multivitamin tablet containing vitamin D(2) 400 IU (10 microg) for 6 months.
Study: 12768070
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (rHuGH) therapy at a dose of 0.2 IU/kg/BW
Study: 11152056
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment according to TCM principles (n = 20)
Study: 8251028
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ranitidine and chlorpheniramine
Study: 2179479
Drug: multidrug chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: multidrug chemotherapy schedule with VM26 and AraC
Study: 2179479
Drug: multidrug chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: multidrug chemotherapy schedule without VM26 and AraC
Study: 7428403
Drug: Prophylactic cephazolin
Normalized name: Cephazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic cephazolin sodium (1 g) given intramuscularly
Study: 7428403
Drug: Prophylactic cephazolin
Normalized name: Cephazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic cephazolin sodium (1 g) given intravenously
Study: 29259061
Drug: Guided physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided physical exercise and dietary therapy
Study: 28374645
Drug: Bromocriptine-QR (B-QR)
Normalized name: QR-313
DrugBank: QR-313 (DB17867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine-QR (B-QR) in high-dose insulin subset
Study: 25896104
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 5 mg twice daily for three days
Study: 25896104
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical capsules for three days)
Study: 24075920
Drug: rHA 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHA 45 μg
Study: 24075920
Drug: rHA 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHA 45 μg with GLA/SE
Study: 24075920
Drug: rHA 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHA 15 μg with GLA/SE
Study: 19059175
Drug: Monthly simulated
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monthly simulated and critiqued oral examinations (MSCE) from 2003 to 2006 classes
Study: 12239234
Drug: Omapatrilat (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omapatrilat (40 or 80 mg)
Study: 12215465
Drug: Fosinopril/Hydrochlorothiazide (FOS/HCTZ;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril/Hydrochlorothiazide (FOS/HCTZ; 20 and 12.5 mg)
Study: 7725767
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg PGE2 intracervical gel
Study: 7725767
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg PGE2 vaginal tablet
Study: 2175140
Drug: beta-endorphin infusion
Normalized name: beta-endorphin human
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-endorphin infusion at 1 microgram.kg‐1.min‐1
Study: 2175140
Drug: placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (normal saline) infusion
Study: 2175140
Drug: beta-endorphin infusion
Normalized name: beta-endorphin human
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-endorphin infusion
Study: 29068865
Drug: Army Preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Army Preparation Drill (PD)
Study: 24405833
Drug: Adalimumab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (20 mg/0.8 ml for patients <30 kg or 40 mg/0.8 ml for patients ≥30 kg, subcutaneous injection every 2 weeks)
Study: 24405833
Drug: Placebo (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.8 ml as appropriate according to body weight, subcutaneous injection every 2 weeks)
Study: 17709835
Drug: Low-dose multi-detector
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose multi-detector row CT (30 mAs, 16 detector rows, 0.75-mm section thickness)
Study: 17709835
Drug: Low-dose multi-detector
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose multi-detector row CT
Study: 15188172
Drug: KLH feeding
Normalized name: KLH
DrugBank: Keyhole limpet hemocyanin (DB05299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KLH feeding (50 and 250 mg) before immunization and booster in normal controls (n = 21)
Study: 15188172
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration in patients with Crohn's disease (n = 12)
Study: 15188172
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration in patients with ulcerative colitis (n = 13)
Study: 11552143
Drug: Dental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental treatment interventions
Study: 9688443
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of ticlopidine (1500 mg followed by 250 mg twice daily)
Study: 9688443
Drug: Standard ticlopidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ticlopidine treatment (250 mg twice daily)
Study: 2642691
Drug: Intravenous clomipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous clomipramine hydrochloride (200 mg) and placebo tablets
Study: 2642691
Drug: Oral clomipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral clomipramine hydrochloride (200 mg) and isotonic saline infusion
Study: 21527582
Drug: Serum 25(OH)D
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 25(OH)D levels <25 nmol/L
Study: 19160533
Drug: Eskimo Skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eskimo Skin Care (oral oil formulation rich in natural stable fish oil)
Study: 9165969
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg tetrahydrocannabinol daily in five doses during active weeks
Study: 27934805
Drug: Budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD) 400 µg/day for 2 months
Study: 27934805
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) 400 µg/day for 2 months
Study: 20234138
Drug: Oral feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral feeding tube (5-Fr) for 12 hours
Study: 16095140
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) for house dust mites (HDMs)
Study: 2865153
Drug: Lipophilic beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipophilic beta-blockers (metoprolol and propranolol)
Study: 18541129
Drug: Generic orlistat
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic orlistat (Ranbaxy Laboratories) 120 mg, 3 times daily for 10 days
Study: 18541129
Drug: Innovator orlistat
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Innovator orlistat (Xenical, Roche Laboratories) 120 mg, 3 times daily for 10 days
Study: 26541531
Drug: Baseline (before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline (before treatment)
Study: 15969876
Drug: FEX 180
Normalized name: fexofenadine hydrochloride 180 MG [Wal-Fex]
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEX 180 mg immediate-release tablet and PSE 240 mg extended-release tablet (control)
Study: 8952866
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg/day for one month
Study: 8952866
Drug: Fluvastatin (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (exact dosage not specified) for one month
Study: 29666135
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy followed by radical radiotherapy (RRT) and stereotactic ablative radiotherapy (SABR) to the primary tumour and SABR/stereotactic radiosurgery (SRS) to all other metastatic sites
Study: 29666135
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy followed by RRT/SABR
Study: 17379046
Drug: Controlled-release (CR)
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release (CR) tramadol 200 mg every morning plus placebo immediate-release (IR) tramadol 50 mg every 4 to 6 hours PRN rescue
Study: 17379046
Drug: Controlled-release (CR)
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release (CR) tramadol
Study: 2226729
Drug: High-dose cytosine
Normalized name: cytosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytosine arabinoside (HD Ara-C) with mitoxantrone (MTX)
Study: 2226729
Drug: High-dose cytosine
Normalized name: cytosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytosine arabinoside (HD Ara-C) with m-amsacrine (AMSA)
Study: 23644930
Drug: 0.5 mg/month
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/month IV ibandronate
Study: 23644930
Drug: 1 mg/month
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/month IV ibandronate
Study: 23644930
Drug: 2.5 mg/day
Normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/day oral risedronate
Study: 21269298
Drug: Frovatriptan (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frovatriptan (5.0 mg)